First Time Loading...

Genmab A/S
NASDAQ:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
NASDAQ:GMAB
Watchlist
Price: 28.33 USD -0.7% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

Genmab A/S operates as an international biotechnology company. [ Read More ]

The intrinsic value of one GMAB stock under the Base Case scenario is 41.92 USD. Compared to the current market price of 28.33 USD, Genmab A/S is Undervalued by 32%.

Key Points:
GMAB Intrinsic Value
Base Case
41.92 USD
Undervaluation 32%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Genmab A/S

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling GMAB stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Genmab A/S

Provide an overview of the primary business activities
of Genmab A/S.

What unique competitive advantages
does Genmab A/S hold over its rivals?

What risks and challenges
does Genmab A/S face in the near future?

Summarize the latest earnings call
of Genmab A/S.

What significant events have occurred
in Genmab A/S over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Genmab A/S.

Provide P/S
for Genmab A/S.

Provide P/E
for Genmab A/S.

Provide P/OCF
for Genmab A/S.

Provide P/FCFE
for Genmab A/S.

Provide P/B
for Genmab A/S.

Provide EV/S
for Genmab A/S.

Provide EV/GP
for Genmab A/S.

Provide EV/EBITDA
for Genmab A/S.

Provide EV/EBIT
for Genmab A/S.

Provide EV/OCF
for Genmab A/S.

Provide EV/FCFF
for Genmab A/S.

Provide EV/IC
for Genmab A/S.

Show me price targets
for Genmab A/S made by professional analysts.

What are the Revenue projections
for Genmab A/S?

How accurate were the past Revenue estimates
for Genmab A/S?

What are the Net Income projections
for Genmab A/S?

How accurate were the past Net Income estimates
for Genmab A/S?

What are the EPS projections
for Genmab A/S?

How accurate were the past EPS estimates
for Genmab A/S?

What are the EBIT projections
for Genmab A/S?

How accurate were the past EBIT estimates
for Genmab A/S?

Compare the revenue forecasts
for Genmab A/S with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Genmab A/S and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Genmab A/S against its competitors.

Analyze the profit margins
(gross, operating, and net) of Genmab A/S compared to its peers.

Compare the P/E ratios
of Genmab A/S against its peers.

Discuss the investment returns and shareholder value creation
comparing Genmab A/S with its peers.

Analyze the financial leverage
of Genmab A/S compared to its main competitors.

Show all profitability ratios
for Genmab A/S.

Provide ROE
for Genmab A/S.

Provide ROA
for Genmab A/S.

Provide ROIC
for Genmab A/S.

Provide ROCE
for Genmab A/S.

Provide Gross Margin
for Genmab A/S.

Provide Operating Margin
for Genmab A/S.

Provide Net Margin
for Genmab A/S.

Provide FCF Margin
for Genmab A/S.

Show all solvency ratios
for Genmab A/S.

Provide D/E Ratio
for Genmab A/S.

Provide D/A Ratio
for Genmab A/S.

Provide Interest Coverage Ratio
for Genmab A/S.

Provide Altman Z-Score Ratio
for Genmab A/S.

Provide Quick Ratio
for Genmab A/S.

Provide Current Ratio
for Genmab A/S.

Provide Cash Ratio
for Genmab A/S.

What is the historical Revenue growth
over the last 5 years for Genmab A/S?

What is the historical Net Income growth
over the last 5 years for Genmab A/S?

What is the current Free Cash Flow
of Genmab A/S?

Financials

Balance Sheet Decomposition
Genmab A/S

Current Assets 33.1B
Cash & Short-Term Investments 28.1B
Receivables 4.9B
Other Current Assets 57m
Non-Current Assets 2.2B
Long-Term Investments 134m
PP&E 1.6B
Intangibles 101m
Other Non-Current Assets 274m
Current Liabilities 2.5B
Other Current Liabilities 2.5B
Non-Current Liabilities 1.2B
Long-Term Debt 680m
Other Non-Current Liabilities 515m
Efficiency

Earnings Waterfall
Genmab A/S

Revenue
16.5B DKK
Cost of Revenue
-226m DKK
Gross Profit
16.2B DKK
Operating Expenses
-10.9B DKK
Operating Income
5.3B DKK
Other Expenses
-969m DKK
Net Income
4.4B DKK

Free Cash Flow Analysis
Genmab A/S

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

GMAB Profitability Score
Profitability Due Diligence

Genmab A/S's profitability score is 73/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Positive Free Cash Flow
Positive Operating Income
Exceptional ROIC
73/100
Profitability
Score

Genmab A/S's profitability score is 73/100. The higher the profitability score, the more profitable the company is.

GMAB Solvency Score
Solvency Due Diligence

Genmab A/S's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

Genmab A/S's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GMAB Price Targets Summary
Genmab A/S

Wall Street analysts forecast GMAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GMAB is 123.74 USD with a low forecast of 27.04 USD and a high forecast of 459.16 USD.

Lowest
Price Target
27.04 USD
5% Downside
Average
Price Target
123.74 USD
337% Upside
Highest
Price Target
459.16 USD
1 521% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

GMAB Price
Genmab A/S

1M 1M
-3%
6M 6M
-1%
1Y 1Y
-29%
3Y 3Y
-11%
5Y 5Y
+75%
10Y 10Y
+846%
Annual Price Range
1 968.5
52w Low
1 854.5
52w High
2 912
Price Metrics
Average Annual Return 29.9%
Standard Deviation of Annual Returns 27.48%
Max Drawdown -44%
Shares Statistics
Market Capitalization 129.2B DKK
Shares Outstanding 64 993 000
Percentage of Shares Shorted
N/A

GMAB Return Decomposition
Main factors of price return

What is price return decomposition?

GMAB News

Last Important Events
Genmab A/S

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Genmab A/S

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Genmab A/S Logo
Genmab A/S

Country

Denmark

Industry

Biotechnology

Market Cap

129.2B USD

Dividend Yield

0%

Description

Genmab A/S operates as an international biotechnology company. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Contact

KOEBENHAVN V
Kalvebod Brygge 43
+4570202728.0
https://www.genmab.com/

IPO

2000-10-01

Employees

1 212

Officers

Co-Founder, President & CEO
Dr. Jan G.J. van de Winkel Ph.D.
Executive VP & CFO
Mr. Anthony Pagano
Executive VP & Chief Legal Officer
Ms. Birgitte Stephensen M.Sc.
Executive VP & Chief Strategy Officer
Dr. Martine J. van Vugt Ph.D.
Senior Director of Clinical Operations & Non-Independent Director
Mr. Martin Schultz
Executive VP, Chief Medical Officer & Head of Experimental Medicines
Dr. Tahamtan Ahmadi
Show More
Senior Director, Head of Antibody Research Materials & Non-Independent Director
Dr. Mijke Zachariasse Ph.D.
Senior Director of Finance Japan & Non-Independent Director
Mr. Takahiro Hamatani
Executive VP & COO
Mr. Anthony Mancini
Senior Director, VP & Head of Investor Relations
Mr. Andrew Carlsen
Show Less

See Also

Discover More
What is the Intrinsic Value of one GMAB stock?

The intrinsic value of one GMAB stock under the Base Case scenario is 41.92 USD.

Is GMAB stock undervalued or overvalued?

Compared to the current market price of 28.33 USD, Genmab A/S is Undervalued by 32%.